Exelixis Inc (MIL:1EXEL) Stock Price, Trades & News

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Financial Strength

9/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	5.06
Equity-to-Asset	0.74
Debt-to-Equity	0.09
Debt-to-EBITDA	0.16
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	15.06	Distress Grey Safe
Beneish M-Score	-3.04	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	18.4
	3-Year EBITDA Growth Rate	68.4
	3-Year EPS without NRI Growth Rate	55.4
	3-Year FCF Growth Rate	63.1
	3-Year Book Growth Rate	2.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	17.59
	Future 3-5Y Total Revenue Growth Rate Estimate	11.32

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.96
	9-Day RSI	10.81
	14-Day RSI	26.47
	3-1 Month Momentum %	12.27
	6-1 Month Momentum %	38.98
	12-1 Month Momentum %	49.24

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.46
	Quick Ratio	3.38
	Cash Ratio	2.32
	Days Inventory	109
	Days Sales Outstanding	46.16
	Days Payable	122.72

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	6.8
	Shareholder Yield %	8.39

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	96.48
	Operating Margin %	40.73
	Net Margin %	35.33
	EBITDA Margin %	41.89
	FCF Margin %	47.52
	OCF Margin %	48.56
	ROE %	42.46
	ROA %	32.03
	ROIC %	48.91
	3-Year ROIIC %	1986.92
	ROC (Joel Greenblatt) %	231.33
	ROCE %	42.81
	Years of Profitability over Past 10-Year	9
	Moat Score	5
	Tariff Resilience Score	8

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	17.11
	Forward PE Ratio	16.22
	PE Ratio without NRI	15.54
	Shiller PE Ratio	38.64
	Price-to-Owner-Earnings	17.26
	PEG Ratio	0.33
	PS Ratio	6.03
	PB Ratio	7.34
	Price-to-Tangible-Book	7.61
	Price-to-Free-Cash-Flow	12.7
	Price-to-Operating-Cash-Flow	12.43
	EV-to-EBIT	12.91
	EV-to-Forward-EBIT	11.45
	EV-to-EBITDA	12.55
	EV-to-Forward-EBITDA	11.05
	EV-to-Revenue	5.26
	EV-to-Forward-Revenue	5.01
	EV-to-FCF	11.06
	Price-to-GF-Value	1.12
	Price-to-Projected-FCF	1.7
	Price-to-Median-PS-Value	1.04
	Price-to-Peter-Lynch-Fair-Value	0.62
	Price-to-Graham-Number	2.29
	Price-to-Net-Current-Asset-Value	22.61
	Price-to-Net-Cash	71.71
	Earnings Yield (Greenblatt) %	7.75
	FCF Yield %	8.59
	Forward Rate of Return (Yacktman) %	23.3

Financials (Next Earnings Date:2026-11-04 Est.)

Annual Quarterly TTM

MIL:1EXEL's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Exelixis Inc Executives

Details

GF Value™: €40.82

MIL:1EXEL

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with 1EXEL. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	2,094.6
	EPS (TTM) (€)	2.735
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	25.09
	14-Day RSI	26.47
	14-Day ATR (€)	0.125088
	20-Day SMA (€)	47.2855
	12-1 Month Momentum %	49.24
	52-Week Range (€)	29.27 - 48.95
	Shares Outstanding (Mil)	247.78

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Exelixis Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Exelixis Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Fourth quarter earnings conference call for 2026	2027-02-10 17:00	In 175 days
Annual report for 2026	2027-02-10	In 174 days
Fourth quarter earnings results for 2026	2027-02-10	In 174 days
Third quarter earnings conference call for 2026	2026-11-04 17:00	In 77 days
Third quarter earnings results for 2026	2026-11-04	In 76 days
Second quarter earnings conference call for 2026	2026-08-05 17:00	46.69 (+0.00%)
Second quarter earnings results for 2026	2026-08-05	46.69 (+0.00%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 10:40	42.08 (+0.00%)
Guidance call for 2026	2026-06-03 11:05	42.08 (-7.13%)
Bernstein 42nd Annual Strategic Decisions Conference	2026-05-27 15:30	43.60 (+0.00%)

Show

Entries

Exelixis Inc Frequently Asked Questions

What is Exelixis Inc(MIL:1EXEL)'s stock price today?

The current price of MIL:1EXEL is €45.90. The 52 week high of MIL:1EXEL is €48.95 and 52 week low is €29.27.

When is next earnings date of Exelixis Inc(MIL:1EXEL)?

The next earnings date of Exelixis Inc(MIL:1EXEL) is 2026-11-04 Est..

Does Exelixis Inc(MIL:1EXEL) pay dividends? If so, how much?

Exelixis Inc(MIL:1EXEL) does not pay dividend.

Press Release

	Subject	Date
	Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm	2026-08-19
	Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky	2026-08-17
	EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law	2026-08-16
	EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)	2026-08-12
	EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis	2026-08-11
	Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)	2026-08-10
	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update	2026-08-05
	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026	2026-07-22
	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	2026-06-22
	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026	2026-05-30

10/Page

Articles on Exelixis Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.